Results 1 to 10 of about 1,183 (82)

Tofacitinib

Reactions Weekly, 2022
Tofacitinib is an oral inhibitor of janus kinases, which is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; its efficacy in the treatment of psoriasis has also been demonstrated in clinical studies. A 10 mg daily dose has been observed to achieve a PASI75 response in 40-64% of the patients with
  +10 more sources

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study

RMD Open, 2023
Objective To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis.Methods Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying ...
Yuko Kaneko, Hideto Kameda, Yoshiya Tanaka, Satoshi Kubo, Koichi Amano, Shingo Nakayamada, Yusuke Miyazaki, Kiyoshi Matsui, Yoshino Inoue, Kunihiro Yamaoka, Takehisa Ogura   +10 more
doaj   +1 more source

Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis

Frontiers in Immunology, 2022
Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease with few therapeutic options. However, the immune system, including natural killer (NK) cells, is linked to ALS progression and may constitute a viable therapeutic ALS
Claudia Figueroa-Romero, Alina Monteagudo, Benjamin J. Murdock, Joshua P. Famie, Ian F. Webber-Davis, Caroline E. Piecuch, Samuel J. Teener, Crystal Pacut, Stephen A. Goutman, Eva L. Feldman   +9 more
doaj   +1 more source

Tofacitinib [PDF]

Hospital Pharmacy, 2013
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Demaris, Kendra, Levien, Terri L, Baker, Danial E   +3 more
openaire   +3 more sources

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

BMC Gastroenterology, 2022
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database.
Michael V. Chiorean, Jessica R. Allegretti, Puza P. Sharma, Benjamin Chastek, Leonardo Salese, Elizabeth J. Bell, Jesse Peterson-Brandt, Joseph C. Cappelleri, Xiang Guo, Nabeel Khan   +9 more
doaj   +1 more source

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

RMD Open, 2023
Objectives Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventional ...
Xiaofeng Zeng, Cunshan Wang, Yi Liu, Jian Xu, Ju Liu, Zhuoli Zhang, Wenfeng Tan, Shengyun Liu, Wei Lin, Weiguo Wan, Zhenyu Jiang, Zhiyi Zhang, Oluwaseyi Dina, Shixue Liu, XiaoMei Leng, Keith Kanik, Jiankang Hu, Jingyang Li, Levent M. Gunay, Cassandra Kinch   +19 more
doaj   +1 more source

Fracture in clinical studies of tofacitinib in rheumatoid arthritis

Therapeutic Advances in Musculoskeletal Disease, 2022
Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk in tofacitinib RA clinical trials. Design: Post hoc analysis.
Karen E. Hansen, Mahta Mortezavi, Edward Nagy, Cunshan Wang, Carol A. Connell, Zaher Radi, Heather J. Litman, Giovanni Adami, Maurizio Rossini   +8 more
doaj   +1 more source

Tofacitinib [PDF]

Drugs in R&D, 2010
Tofacitinib (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant, is being developed by Pfizer for the treatment of rheumatoid arthritis, inflammatory bowel disease, dry eyes, ankylosing spondylitis, psoriasis, psoriatic arthritis, and for the prevention of transplant rejection.
openaire   +3 more sources

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis

RMD Open, 2022
Objective Post hoc analysis of pooled data from nine randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) on residual pain in patients with
Maxime Dougados, Peter C Taylor, Clifton O Bingham, Lisy Wang, Lara Fallon, Satrajit Roychoudhury, Yves Brault, Meriem Kessouri   +7 more
doaj   +1 more source

Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore

BMC Gastroenterology, 2023
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We evaluated tofacitinib efficacy and safety in the 52-week maintenance study, OCTAVE Sustain, by baseline Mayo endoscopic subscore (MES ...
Scott D. Lee, Jessica R. Allegretti, Flavio Steinwurz, Susan B. Connelly, Nervin Lawendy, Jerome Paulissen, Krisztina B. Gecse   +6 more
doaj   +1 more source